ANO31905 in Combination With Chemotherapy for CLDN18.2-Positive Locally Advanced Unresectable or Metastatic Pancreatic Cancer
ANO31905 in Combination With Chemotherapy for CLDN18.2-Positive Locally Advanced Unresectable or Metastatic Pancreatic Cancer
Recruiting · NCT07444541 · Registry updated 2026-07-27Clinical trials
Swipe the table sideways for more columns.
| Trial | Conditions | Status | Phase | Updated | More info | NCT ID |
|---|---|---|---|---|---|---|
| ANO31905 in Combination With Chemotherapy for CLDN18.2-Positive Locally Advanced Unresectable or Metastatic Pancreatic Cancer | Digestive System Diseases, Digestive System Neoplasms, Neoplasms by Site, endocrine system disorder, malignant endocrine neoplasm, malignant pancreatic neoplasm, neoplasm, pancreas disorder, pancreatic neoplasm | Recruiting | Phase 1 / Phase 2 | 2026-07-27 | NCT07444541 |
1 results · Page 1 of 1
Organizations
Swipe the table sideways for more columns.
| Organizations | Linked trials |
|---|---|
| Anova Innovation Limited | 1 |
1 results · Page 1 of 1
Research sites
Swipe the table sideways for more columns.
| Research sites | City | Country | Linked trials |
|---|---|---|---|
| California Research Institute | Los Angeles | United States | 15 |